Ingrid Hedenfalk
21 – 30 of 98
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Protein signature predicts response to neoadjuvant treatment with chemotherapy and bevacizumab in HER2-negative breast cancers
- Contribution to journal › Article
-
Mark
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
- Contribution to journal › Article
-
Mark
Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer
- Contribution to journal › Article
-
Mark
Common Susceptibility Loci for Male Breast Cancer
- Contribution to journal › Article
-
Mark
Homologous recombination repair mechanisms in serous endometrial cancer
- Contribution to journal › Article
- 2020
-
Mark
Simvastatin is a potential candidate drug in ovarian clear cell carcinomas
- Contribution to journal › Article
-
Mark
A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients
- Contribution to journal › Article
-
Mark
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
- Contribution to journal › Article
-
Mark
SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery
- Contribution to journal › Article
-
Mark
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer
- Contribution to journal › Article
